The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice

G. Grassia, M. Maddaluno, A. Guglielmotti, G. Mangano, G. Biondi, P. Maffia, A. Ialenti

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Aims Bindarit is an original compound with peculiar anti-inflammatory activity due to a selective inhibition of a subfamily of inflammatory chemokines, including the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8. In this study, we investigated the effect of bindarit on neointima formation using two animal models of arterial injury: rat carotid artery balloon angioplasty and wire-induced carotid injury in apolipoprotein E-deficient (apoE−/−) mice. Methods and results Treatment of rats with bindarit (200 mg/kg/day) significantly reduced balloon injury-induced neointima formation by 39% at day 14 without affecting re-endothelialization and reduced the number of medial and neointimal proliferating cells at day 7 by 54 and 30%, respectively. These effects were associated with a significant reduction of MCP-1 levels both in sera and in injured carotid arteries of rats treated with bindarit. In addition, in vitro data showed that bindarit (10-300 µM) reduced rat vascular smooth muscle cell (VSMC) proliferation, migration, and invasion, processes contributing to the injury-induced neointima formation in vivo. Similar results were observed in hypercholesterolaemic apoE−/− mice in which bindarit administration resulted in a 42% reduction of the number of proliferating cells at day 7 after carotid injury and in a 47% inhibition of neointima formation at day 28. Analysis of the cellular composition in neointimal lesions of apoE−/− mice treated with bindarit showed that the relative content of macrophages and the number of VSMCs were reduced by 66 and 30%, respectively, compared with the control group. Conclusion This study demonstrates that bindarit is effective in reducing neointima formation in both non-hyperlipidaemic and hyperlipidaemic animal models of vascular injury by a direct effect on VSMC proliferation and migration and by reducing neointimal macrophage content. All of these data were associated with the inhibition of MCP-1 production.
Original languageEnglish
Pages (from-to)485-493
Number of pages8
JournalCardiovascular Research
Volume84
Issue number3
DOIs
Publication statusPublished - 1 Dec 2009

Fingerprint

Neointima
Anti-Inflammatory Agents
Apolipoproteins E
Wounds and Injuries
Vascular Smooth Muscle
Smooth Muscle Myocytes
Cell Movement
Animal Models
Macrophages
Cell Proliferation
Carotid Artery Injuries
Balloon Angioplasty
bindarit
Chemokine CCL2
Vascular System Injuries
Carotid Arteries
Chemokines
Cell Count
Control Groups

Keywords

  • bindarit
  • neointima hyperplasia
  • monocyte chemoattractant protein-1
  • macrophages
  • vascular smooth muscle cells

Cite this

Grassia, G., Maddaluno, M., Guglielmotti, A., Mangano, G., Biondi, G., Maffia, P., & Ialenti, A. (2009). The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice. Cardiovascular Research, 84(3), 485-493. https://doi.org/10.1093/cvr/cvp238
Grassia, G. ; Maddaluno, M. ; Guglielmotti, A. ; Mangano, G. ; Biondi, G. ; Maffia, P. ; Ialenti, A. / The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice. In: Cardiovascular Research. 2009 ; Vol. 84, No. 3. pp. 485-493.
@article{37d22df49d6d450d978fbf6553ec3ce5,
title = "The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice",
abstract = "Aims Bindarit is an original compound with peculiar anti-inflammatory activity due to a selective inhibition of a subfamily of inflammatory chemokines, including the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8. In this study, we investigated the effect of bindarit on neointima formation using two animal models of arterial injury: rat carotid artery balloon angioplasty and wire-induced carotid injury in apolipoprotein E-deficient (apoE−/−) mice. Methods and results Treatment of rats with bindarit (200 mg/kg/day) significantly reduced balloon injury-induced neointima formation by 39{\%} at day 14 without affecting re-endothelialization and reduced the number of medial and neointimal proliferating cells at day 7 by 54 and 30{\%}, respectively. These effects were associated with a significant reduction of MCP-1 levels both in sera and in injured carotid arteries of rats treated with bindarit. In addition, in vitro data showed that bindarit (10-300 µM) reduced rat vascular smooth muscle cell (VSMC) proliferation, migration, and invasion, processes contributing to the injury-induced neointima formation in vivo. Similar results were observed in hypercholesterolaemic apoE−/− mice in which bindarit administration resulted in a 42{\%} reduction of the number of proliferating cells at day 7 after carotid injury and in a 47{\%} inhibition of neointima formation at day 28. Analysis of the cellular composition in neointimal lesions of apoE−/− mice treated with bindarit showed that the relative content of macrophages and the number of VSMCs were reduced by 66 and 30{\%}, respectively, compared with the control group. Conclusion This study demonstrates that bindarit is effective in reducing neointima formation in both non-hyperlipidaemic and hyperlipidaemic animal models of vascular injury by a direct effect on VSMC proliferation and migration and by reducing neointimal macrophage content. All of these data were associated with the inhibition of MCP-1 production.",
keywords = "bindarit, neointima hyperplasia, monocyte chemoattractant protein-1, macrophages, vascular smooth muscle cells",
author = "G. Grassia and M. Maddaluno and A. Guglielmotti and G. Mangano and G. Biondi and P. Maffia and A. Ialenti",
year = "2009",
month = "12",
day = "1",
doi = "10.1093/cvr/cvp238",
language = "English",
volume = "84",
pages = "485--493",
journal = "Cardiovascular Research",
issn = "0008-6363",
number = "3",

}

Grassia, G, Maddaluno, M, Guglielmotti, A, Mangano, G, Biondi, G, Maffia, P & Ialenti, A 2009, 'The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice', Cardiovascular Research, vol. 84, no. 3, pp. 485-493. https://doi.org/10.1093/cvr/cvp238

The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice. / Grassia, G.; Maddaluno, M.; Guglielmotti, A.; Mangano, G.; Biondi, G.; Maffia, P.; Ialenti, A.

In: Cardiovascular Research, Vol. 84, No. 3, 01.12.2009, p. 485-493.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice

AU - Grassia, G.

AU - Maddaluno, M.

AU - Guglielmotti, A.

AU - Mangano, G.

AU - Biondi, G.

AU - Maffia, P.

AU - Ialenti, A.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Aims Bindarit is an original compound with peculiar anti-inflammatory activity due to a selective inhibition of a subfamily of inflammatory chemokines, including the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8. In this study, we investigated the effect of bindarit on neointima formation using two animal models of arterial injury: rat carotid artery balloon angioplasty and wire-induced carotid injury in apolipoprotein E-deficient (apoE−/−) mice. Methods and results Treatment of rats with bindarit (200 mg/kg/day) significantly reduced balloon injury-induced neointima formation by 39% at day 14 without affecting re-endothelialization and reduced the number of medial and neointimal proliferating cells at day 7 by 54 and 30%, respectively. These effects were associated with a significant reduction of MCP-1 levels both in sera and in injured carotid arteries of rats treated with bindarit. In addition, in vitro data showed that bindarit (10-300 µM) reduced rat vascular smooth muscle cell (VSMC) proliferation, migration, and invasion, processes contributing to the injury-induced neointima formation in vivo. Similar results were observed in hypercholesterolaemic apoE−/− mice in which bindarit administration resulted in a 42% reduction of the number of proliferating cells at day 7 after carotid injury and in a 47% inhibition of neointima formation at day 28. Analysis of the cellular composition in neointimal lesions of apoE−/− mice treated with bindarit showed that the relative content of macrophages and the number of VSMCs were reduced by 66 and 30%, respectively, compared with the control group. Conclusion This study demonstrates that bindarit is effective in reducing neointima formation in both non-hyperlipidaemic and hyperlipidaemic animal models of vascular injury by a direct effect on VSMC proliferation and migration and by reducing neointimal macrophage content. All of these data were associated with the inhibition of MCP-1 production.

AB - Aims Bindarit is an original compound with peculiar anti-inflammatory activity due to a selective inhibition of a subfamily of inflammatory chemokines, including the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8. In this study, we investigated the effect of bindarit on neointima formation using two animal models of arterial injury: rat carotid artery balloon angioplasty and wire-induced carotid injury in apolipoprotein E-deficient (apoE−/−) mice. Methods and results Treatment of rats with bindarit (200 mg/kg/day) significantly reduced balloon injury-induced neointima formation by 39% at day 14 without affecting re-endothelialization and reduced the number of medial and neointimal proliferating cells at day 7 by 54 and 30%, respectively. These effects were associated with a significant reduction of MCP-1 levels both in sera and in injured carotid arteries of rats treated with bindarit. In addition, in vitro data showed that bindarit (10-300 µM) reduced rat vascular smooth muscle cell (VSMC) proliferation, migration, and invasion, processes contributing to the injury-induced neointima formation in vivo. Similar results were observed in hypercholesterolaemic apoE−/− mice in which bindarit administration resulted in a 42% reduction of the number of proliferating cells at day 7 after carotid injury and in a 47% inhibition of neointima formation at day 28. Analysis of the cellular composition in neointimal lesions of apoE−/− mice treated with bindarit showed that the relative content of macrophages and the number of VSMCs were reduced by 66 and 30%, respectively, compared with the control group. Conclusion This study demonstrates that bindarit is effective in reducing neointima formation in both non-hyperlipidaemic and hyperlipidaemic animal models of vascular injury by a direct effect on VSMC proliferation and migration and by reducing neointimal macrophage content. All of these data were associated with the inhibition of MCP-1 production.

KW - bindarit

KW - neointima hyperplasia

KW - monocyte chemoattractant protein-1

KW - macrophages

KW - vascular smooth muscle cells

UR - http://dx.doi.org/10.1093/cvr/cvp238

U2 - 10.1093/cvr/cvp238

DO - 10.1093/cvr/cvp238

M3 - Article

VL - 84

SP - 485

EP - 493

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 3

ER -

Grassia G, Maddaluno M, Guglielmotti A, Mangano G, Biondi G, Maffia P et al. The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice. Cardiovascular Research. 2009 Dec 1;84(3):485-493. https://doi.org/10.1093/cvr/cvp238